What is Pathos AI?
Pathos AI is an AI-enabled biotechnology company dedicated to revolutionizing drug development. By harnessing advanced technology, the company aims to deliver precision medicine to patients through strategic collaborations with pharmaceutical giants. Their focus on re-engineering the drug discovery and development pipeline leverages artificial intelligence to accelerate the identification and validation of novel therapeutic candidates, promising a more efficient and targeted approach to healthcare solutions.
How much funding has Pathos AI raised?
Pathos AI has raised a total of $427M across 2 funding rounds:
Series C
$62M
Series D
$365M
Series C (2024): $62M with participation from New Enterprise Associates, Builders VC, Lightbank, and Revolution Growth
Series D (2025): $365M led by New Enterprise Associates, Lightbank, Growth Revolution, and Builders VC
Key Investors in Pathos AI
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on empowering entrepreneurs and building transformative businesses across various technology sectors.
Builders VC
Builders VC is a venture capital firm that specializes in modernizing traditional industries through strategic investments in innovative technologies, with a particular interest in healthcare and complex problem-solving.
Lightbank
Lightbank is an investment firm based in Chicago that provides capital and strategic guidance to innovative startups, aiming to foster growth within the technology ecosystem.
What's next for Pathos AI?
The recent major strategic investment in Pathos AI signals a strong validation of its innovative approach to drug development. This capital infusion is expected to fuel the company's ongoing research and development efforts, potentially enabling the expansion of its platform capabilities and the acceleration of its pipeline. Pathos AI is poised to further solidify its position in the precision medicine landscape, driving forward the integration of AI into pharmaceutical R&D and bringing life-changing therapies to market.
See full Pathos AI company page
